TRENTON, N.J. - Just three months before a top-selling drug gets U.S. generic competition, a generic company has paid nearly $445 million to end a decadelong, twist-filled patent-infringement ...

The agreement had a catch -- if the feds didn't like it, then Apotex would be allowed to begin production of generic Plavix without BMS's permission, and BMS would have to wait five days before ...

Toronto, ON - Apotex Corp (Toronto, ON) today launched its version of generic clopidogrel bisulfate 75-mg tablets, backing out of a settlement agreement with Plavix manufacturer and marketers ...

A federal judge ordered Apotex Corp. to pay $442.2 million in damages for selling generic versions of anticlotting drug Plavix in 2006, a violation of Sanofi-Aventis SA's U.S. patent for the ...

TRENTON, N.J. -- Just three months before the world's second-best-selling drug gets U.S. generic competition, a generic company has paid nearly $445 million to finally end a decadelong, twist ...

NEW YORK (MarketWatch) -- A lawyer for generic drug maker Apotex Inc. urged a federal judge on Monday to declare Sanofi-Aventis's (SNY) patent for popular blood thinner Plavix invalid as opening ...

Apotex has been unsuccessful in its bid to secure the rights to market a generic version of Sanofi-Aventis’ blockbuster blood thinner Plavix (clopidogrel) in Canada. Apotex has been unsuccessful in ...

A Canadian drugmaker, Apotex, said Tuesday that it has begun shipping a generic version of Plavix, one of the top-selling prescription drugs in the world, to retailers in the United States.

August 9, 2006 — Apotex Corp yesterday launched its version of generic clopidogrel bisulfate 75-mg tablets, backing out of a settlement agreement with Plavix manufacturer and marketers Bristol ...